Research
Hormonal
Future research is needed to determine the ideal SGLT-2 inhibitor or GLP-1RA for weight loss management and the efficacy of combination therapies.
Practitioners should stay informed about ongoing research for optimal weight loss strategies using these medications.
StrongSupportsmedium confidence
Future research is warranted to determine the ideal SGLT-2 inhibitor or GLP-1RA for weight loss management, and additional randomized controlled trials (RCTs) are needed to determine the efficacy and tolerability of potential combination therapies with SGLT-2 inhibitors and GLP-1RAs.
Why this rating
Based on the systematic review of sixteen randomized controlled trials.
Source
The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review
Sachin M. Shridharani et al. · Aesthetic Surgery Journal · 2023
DOI 10.1093/asj/sjad240
systematic_review · n=10492Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →